Published in
Apr 2016 ; US $ 1295
Onwards;Publisher: Business Monitor International
BMI View: Although we retain our view that the UK will remain a member of the European Union after the Brexit referendum to be held on June 23, uncertainty over the outcome increased in the first months of 2016, and a Brexit would pose significant challenges to the UK and European pharmaceutical industries. The negative implications of a Brexit for the drug industry would include a reduction of scientific...
Published in
Apr 2016 ; US $ 1295
Onwards;Publisher: Business Monitor International
BMI View: Qatar’s pharmaceuticals and healthcare sectors will continue to grow despite challenges facing the government’s revenue streams. Both an increase in public spending on health, including in infrastructure projects, and the rising participation of the private sector in healthcare funding will sustain robust sector growth over the forecast period. In fact, while Qatar will likely...
Published in
Apr 2016 ; US $ 1295
Onwards;Publisher: Business Monitor International
BMI View: Our growth outlook for Israel’s pharmaceutical sector is underpinned by the government package to systematically bolster the public health system through targeted investment in health resources and infrastructure. Concerted efforts to grow the interface between private and public medicine and an improving intellectual property picture will ensure commercial opportunities remain for...
Published in
Apr 2016 ; US $ 1295
Onwards;Publisher: Business Monitor International
BMI View: With sanctions lifted, Iran has improving prospects of opening up to a wider diversity of trading partners and providing strategic opportunities for multinational pharmaceutical companies. By reintegrating into the financial transaction system SWIFT, the import of pharmaceutical-related products will ease and prevent future drug shortages. Both innovative and generic drugmakers will look...
Stay In Touch